Is Ozempic Causing Your Gastroparesis? Diagnosis and Next Steps in North Carolina

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Targeted Exposure Awareness

If you're experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be dealing with gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance have established that certain medications can disrupt gastrointestinal motility, and GLP-1 receptor agonists are now under scrutiny for this effect. This page explains how gastroparesis is diagnosed in North Carolina and what follow-up steps you should consider.

Ozempic and Gastrointestinal Adverse Reactions: The Medical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known effects, gastrointestinal adverse reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical diagnosis often involves gastric emptying scintigraphy. While Ozempic's prescribing information does not explicitly list gastroparesis as an adverse reaction, it does report gastrointestinal adverse reactions with a frequency of less than 5%, including dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the pharmacologic action of GLP-1 receptor agonists, which slow gastric emptying, provides a mechanistic pathway linking Ozempic to gastroparesis. Delayed gastric emptying is a known effect of GLP-1 receptor agonists, and prolonged use may exacerbate or unmask gastroparesis in susceptible individuals.

Adequacy of Warnings and Risk Considerations

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information for Ozempic includes a warning about serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis. The label notes that gastrointestinal adverse reactions are common and that patients may discontinue treatment due to these reactions, but it does not explicitly address the risk of developing gastroparesis. This gap in labeling may affect the ability of patients and healthcare providers to recognize and manage the condition early. For affected patients in North Carolina, settlement-related considerations involve the statute of limitations for filing a claim. In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury is discovered or reasonably should have been discovered. For claims involving gastroparesis allegedly caused by Ozempic, the timeline between exposure and documented harm is critical. Patients who experienced gastrointestinal symptoms during dose escalation or after prolonged use should document the onset of symptoms, the date of diagnosis, and any medical records linking the condition to Ozempic use. The statute of limitations may begin when the patient first became aware of the potential link between Ozempic and gastroparesis, which could be later than the initial onset of symptoms. Settlement-related considerations also include the strength of evidence linking Ozempic to gastroparesis. While clinical trials show increased gastrointestinal adverse reactions, the specific diagnosis of gastroparesis is not listed in the label. Patients may need to rely on expert testimony and mechanistic evidence to establish causation. The risk of gastroparesis may be dose-dependent, as higher doses of Ozempic (2 mg) were associated with more gastrointestinal adverse reactions than lower doses (1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This dose-response relationship could support claims that higher exposure increases risk. In summary, patients in North Carolina who developed gastroparesis after using Ozempic should be aware of the statute of limitations, which typically runs three years from discovery of the injury. The adequacy of warnings is questionable, as the label does not specifically mention gastroparesis despite the known gastrointestinal effects of GLP-1 receptor agonists. The timeline between exposure and harm should be carefully documented, including the start of Ozempic use, dose escalation, and the onset of gastroparesis symptoms. Legal consultation is recommended to assess individual circumstances and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury is discovered or reasonably should have been discovered. For Ozempic-induced gastroparesis, this means the clock typically starts when you become aware of the link between your gastroparesis and Ozempic use. It is crucial to document the onset of symptoms, diagnosis date, and any medical records connecting the condition to Ozempic. Consulting an attorney promptly is recommended to ensure your claim is filed within the applicable deadline.

Does Ozempic's label warn about gastroparesis?

No, Ozempic's prescribing information does not explicitly list gastroparesis as an adverse reaction. It does report gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, dyspepsia, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about the risk of developing gastroparesis, despite the known mechanism of GLP-1 receptor agonists slowing gastric emptying. This gap in labeling may affect the ability to recognize and manage the condition early.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.